Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age18+
SponsorAtlantic Health System
About this trial
The goal of this clinical trial is to learn if silodosin works to treat lower urinary tract symptoms (LUTS) in female patients with multiple sclerosis (MS). It will also learn about the effect of the drug on voiding parameters. The main questions it aims to answer are:
Does silodosin improve lower urinary tract symptoms based on questionnaires? Does silodosin change Uroflowmetry parameters in female patients with MS? Researchers will compare silodosin to a placebo (a look-alike substance that contains no drug) to see if silodosin works to treat LUTS in female patients with MS.
Participants will:
Take silodosin or a placebo every day for 8 weeks Visit the clinic before initiating the medication and after 8 weeks of taking the medication for questionnaires and tests
Eligibility criteria
Qualifiers
Female patients with a diagnosis of multiple sclerosis
Age > 18
Moderate to severe lower urinary tract symptoms as defined by an AUASS score > 8
No UTI
Disqualifiers
Treatment with alpha-blocker, B3 agonist, or anticholinergic medication within the last 6 weeks
Treatment with sacral neuromodulation, bladder Botox, or posterior tibial nerve stimulation within the last 9 months
Renal impairment with CrCl < 30
PVR > 300
Trial design
Treatments tested in this trial
- Silodosin 8 mg
- Placebo
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov